Designing biologic selectivity for inflammatory bowel disease – Role of vedolizumab

Drug Design, Development and Therapy

Volumn 9, Issue , 2014, Pages 147-154

  Krupka, Niklas ^a   Baumgart, Daniel C ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Anti 4 7; Crohn s disease; LDP 02; MLN 02; MLN0002; Ulcerative colitis; Vedolizumab

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; NATALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ARTHRALGIA; DISEASE SEVERITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; FEVER; HEADACHE; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE MIGRATION INHIBITION; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHINOPHARYNGITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL MOVEMENT; DRUG DESIGN; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919684811     PISSN: 11778881     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S50348     Document Type: Review

References (61)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369(9573):1627–1640.
2. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380(9853): 1590–1605.
3. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcer-ative colitis. Lancet. 2012;380(9853):1606–1619.
4. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in infammatory bowel disease. Nature. 2011;474(7351):298–306.
5. Barrett JC, Lee JC, Lees CW, et al; UK IBD Genetics Consortium; Wellcome Trust Case Control Consortium 2. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009;41(12):1330–1334.
6. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42(12):1118–1125.
7. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43(3):246–252.
8. Selby WS, Janossy G, Bofill M, Jewell DP. Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques. Gut. 1984;25(1): 32–40.
9. Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis. Infammopharmacology. 2012;20(1):1–18.
10. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–687.
11. Muller WA. Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol. 2011;6:323–344.
12. Streeter PR, Berg EL, Rouse BT, Bargatze RF, Butcher EC. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature. 1988;331(6151):41–46.
13. Hu MC, Crowe DT, Weissman IL, Holzmann B. Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer’s patch-specific lymphocyte homing. Proc Natl Acad Sci U S A. 1992;89(17):8254–8258.
14. Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell. 1993;74(1):185–195.
15. Briskin MJ, McEvoy LM, Butcher EC. MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1. Nature. 1993;363(6428):461–464.
16. Erle DJ, Briskin MJ, Butcher EC, Garcia-Pardo A, Lazarovits AI, Tidswell M. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol. 1994; 153(2):517–528.
17. Wagner N, Löhler J, Kunkel EJ, et al. Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature. 1996; 382(6589):366–370.
18. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997; 151(1):97–110.
19. Binion DG, West GA, Ina K, Ziats NP, Emancipator SN, Fiocchi C. Enhanced leukocyte binding by intestinal microvascular endothelial cells in infammatory bowel disease. Gastroenterology. 1997;112(6): 1895–1907.
20. Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group. Maintenance infiximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549.
21. Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infiximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2(10):912–920.
22. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infiximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
23. Dave M, Purohit T, Razonable R, Loftus EV Jr. Opportunistic infections due to inflammatory bowel disease therapy. Infamm Bowel Dis. 2014;20(1):196–212.
24. Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol. 2013;108(12): 1835–1842, quiz 1843.
25. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–1239.
26. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6(6):644–653.
27. Marsal J, Agace WW. Targeting T-cell migration in inflammatory bowel disease. J Intern Med. 2012;272(5):411–429.
28. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4 beta1 integrin. Nature. 1992;356(6364): 63–66.
29. Miller DH, Khan OA, Sheremata WA, et al; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15–23.
30. Polman CH, O’Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.
31. Rudick RA, Stuart WH, Calabresi PA, et al; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–923.
32. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease. Gastroenterology. 2001;121(2): 268–274.
33. Ghosh S, Goldin E, Gordon FH, et al; Natalizumab Pan-European Study Group. Natalizumab for active Crohn’s disease. N Engl J Med. 2003;348(1):24–32.
34. Sandborn WJ, Colombel JF, Enns R, et al; International Efficacy of Natalizumab as Active Crohn’s Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–1925.
35. Targan SR, Feagan BG, Fedorak RN, et al; International Efficacy of Natalizumab in Crohn’s Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672–1683.
36. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther. 2002;16(4):699–705.
37. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005; 353(4):369–374.
38. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375–381.
39. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353(4):362–368.
40. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specifcity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for infamma-tory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864–875.
41. Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Infamm Bowel Dis. 2012;18(8):1470–1479.
42. Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
43. Sandborn WJ, Feagan BG, Rutgeerts P, et al; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721.
44. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha4 beta7. Gastroenterology. 1996;111(5):1373–1380.
45. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352(24):2499–2507.
46. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6(12):1370–1377.
47. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439–444.
48. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–1629.
49. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627.e3.
50. Sandborn WJ, Feagan BG, Reinisch W, et al. Mo1217 Effects of continued vedolizumab therapy for Crohn’s disease in week 6 induction therapy nonresponders. Digestive Disease Week 2014; 2014 May 3–6; Chicago, IL. Gastroenterology. 2014;146(5 Suppl 1):S-588.
51. Feagan BG, Sandborn W, Smyth MD, Sankoh S, Parikh A, Fox I. Mo1222 Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders. Digestive Disease Week 2014; 2014 May 3–6; Chicago, IL. Gastroenterology. 2014;146(5 Suppl 1): S-590.
52. Colombel J-F, Sands BE, Feagan BG, et al. 643 Integrated safety analysis of vedolizumab for the treatment of ulcerative colitis or Crohn’s disease. Digestive Disease Week 2013; 2013 May 18–21; Orlando, FL. Gastroenterology. 2013;144(5 Suppl 1):S-113.
53. Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014;160(10):704–711.
54. Fedyk ER, Wyant T, Yang LL, et al. Exclusive antagonism of the α4β7 integrin by vedolizumab confrms the gut-selectivity of this pathway in primates. Infamm Bowel Dis. 2012;18(11):2107–2119.
55. Haanstra KG, Hofman SO, Lopes Estêvão DM, et al. Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol. 2013;190(5):1961–1973.
56. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–1880.
57. Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309–318.
58. Pullen N, Molloy E, Carter D, et al. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol. 2009;157(2):281–293.
59. Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut. 2011;60(8):1068–1075.
60. Pan WJ, Hsu H, Rees WA, et al. Pharmacology of AMG 181, a human anti-α4β7 antibody that specifcally alters traffcking of gut-homing T cells. Br J Pharmacol. 2013;169(1):51–68.
61. Pan WJ, Köck K, Rees WA, et al. Clinical pharmacology of AMG 181, a gut-specifc human anti-α4β7 monoclonal antibody, for treating infam-matory bowel diseases. Br J Clin Pharmacol. Epub 2014 May 6.